- Home
- DMA vs ACRV Comparison
DMA vs ACRV Comparison
Compare DMA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | ACRV |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.8M | 95.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | DMA | ACRV |
|---|---|---|
| Price | $9.00 | $2.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 34.6K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.78 | $1.05 |
| 52 Week High | $8.00 | $8.00 |
Technical Indicators
Market Signals| Indicator | DMA | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 44.99 |
| Support Level | $9.00 | $1.57 |
| Resistance Level | $9.15 | $3.56 |
| Average True Range (ATR) | 0.12 | 0.31 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 50.00 | 20.85 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.